| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net loss | |||||||||
-16,851 | -11,883 | -20,402 | -22,053 | -22,461 | -25,494 | -8,251 | -26,568 | -23,222 | -18,818 |
Adjustments to reconcile net loss to net cash from operating activities: | |||||||||
Depreciation and amortization | |||||||||
721 | 356 | 553 | 1,022 | 424 | 369 | 339 | 281 | 169 | 165 |
Change in fair value of earn-out milestone liability | |||||||||
3,189 | 3,630 | 649 | - | - | - | - | - | - | - |
Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments | |||||||||
-400 | - | - | - | - | - | - | - | - | - |
Change in fair value of earn-out milestone liability | |||||||||
- | - | - | 733 | -257 | 213 | - | - | - | - |
Cash received for non-refundable research and development fee | |||||||||
- | - | - | - | - | - | 5,000 | - | - | - |
Change in fair value of common stock warrant liability | |||||||||
- | - | - | - | - | - | - | - | 81 | 573 |
Recognition of deferred revenue | |||||||||
- | - | - | -500 | -500 | -500 | -500 | - | - | - |
Impairment of in-process research and development | |||||||||
- | - | - | 1,444 | - | - | - | - | - | - |
Change in fair value of common stock warrant liability | |||||||||
- | - | - | - | 61 | -204 | -8,090 | 4,117 | - | - |
Stock-based compensation costs | |||||||||
2,286 | 4,604 | 1,105 | 1,511 | 1,849 | 2,585 | 1,235 | 1,143 | 1,036 | 1,295 |
Stock-based compensation | |||||||||
- | - | - | - | - | - | - | - | -171 | -357 |
Shares issues in upon vesting of stock awards | |||||||||
5 | - | 235 | 0 | - | - | - | - | 71 | 18 |
Deferred income tax asset | |||||||||
-1,819 | - | - | - | - | - | - | - | - | - |
Shares issued in exchange for services | |||||||||
- | 29 | - | - | - | - | - | - | - | - |
Impairment of in-process research and development | |||||||||
- | 4,510 | 2,520 | - | - | - | - | - | - | - |
Amortization of deferred finance charges and debt discount associated with notes payable | |||||||||
386 | 199 | - | - | - | - | - | - | - | - |
Shares issued out of treasury | |||||||||
- | - | - | 101 | 86 | 64 | 98 | 107 | 60 | - |
Amortization of deferred finance charges and debt discount associated with notes payable | |||||||||
- | - | 35 | 236 | 438 | 437 | 336 | 43 | - | - |
Amortization of patent license fee | |||||||||
- | - | - | 5 | 7 | 7 | 7 | 7 | 7 | 7 |
Change in deferred rent liability | |||||||||
- | -8 | 59 | -35 | -29 | -24 | -18 | 55 | 65 | - |
Loss realized on sale of investment securities | |||||||||
- | - | - | -0 | 0 | -24 | -92 | -7 | - | - |
Net changes in: | |||||||||
Accrued interest on investment securities | |||||||||
-46 | 13 | - | -22 | -183 | -2 | 146 | -177 | - | - |
Advances, deposits and other current assets | |||||||||
- | - | 50 | - | - | -1 | 116 | -18 | -4 | -20 |
Refundable income taxes | |||||||||
- | - | - | - | - | - | - | - | - | -806 |
Advances, deposits and other current assets | |||||||||
901 | 362 | -115 | - | - | -77 | 121 | -585 | 393 | -340 |
Other assets | |||||||||
74 | 250 | - | 14 | -246 | - | - | - | - | - |
Accounts payable - trade | |||||||||
-157 | -396 | 537 | 48 | -859 | 1,764 | -887 | -1,344 | -538 | 2,357 |
Deferred revenue | |||||||||
-500 | -500 | -500 | - | - | - | - | - | - | - |
Other accrued liabilities | |||||||||
-611 | 303 | -200 | 563 | -536 | -251 | 1,497 | -776 | -92 | 655 |
Net cash (used in) operating activities: | |||||||||
-20,258 | -7,041 | -16,642 | -18,379 | -20,830 | -21,353 | -9,525 | -22,144 | -22,742 | -13,367 |
Cash flows from investing activities: | |||||||||
Purchases of investment securities | |||||||||
23,829 | 16,973 | 12,734 | 4,511 | 21,074 | 29,825 | 66,323 | 16,394 | 10,659 | 11,844 |
Proceeds from sale and maturity of investment securities | |||||||||
30,115 | 15,480 | 1,680 | 13,635 | 34,460 | 42,812 | 37,194 | 18,478 | 395 | 17,057 |
Refund on security for letter of credit | |||||||||
- | - | 100 | - | - | - | - | - | - | - |
Cash used in acquisition of EGEN, Inc., net of cash received | |||||||||
- | - | - | - | - | 2,820 | - | - | - | - |
Refund on security for letter of credit | |||||||||
- | - | - | 0 | 50 | 50 | 50 | - | -250 | - |
Purchases of property and equipment | |||||||||
349 | 138 | 38 | 62 | 109 | 672 | 57 | 613 | 573 | 6 |
Net cash used in investing activities | |||||||||
5,935 | -1,632 | -10,992 | 9,060 | 13,326 | 9,543 | -29,136 | 1,470 | -11,087 | 5,206 |
Cash flows from financing activities: | |||||||||
Proceeds from sale of common stock equity, net of issuance costs | |||||||||
7,844 | 858 | - | - | - | 13,788 | 15,622 | - | 48,082 | 2,484 |
Proceeds from sale of common stock equity, net of issuance costs | |||||||||
- | - | 17,910 | 6,775 | 7,736 | - | 13,616 | - | 4,324 | - |
Proceeds from exercise of common stock options | |||||||||
- | - | - | - | - | 0 | 184 | 697 | - | - |
Proceeds from note payable, net of issuance costs | |||||||||
- | 9,725 | - | - | - | 5,000 | 4,763 | 4,825 | 144 | - |
Proceeds from exercise of common stock warrants | |||||||||
- | - | 21,140 | 2 | 0 | 0 | 261 | 10,106 | - | - |
Principal payments on note payable | |||||||||
- | - | 2,595 | 4,099 | 3,654 | 10 | 5,060 | 110 | 142 | 108 |
Net cash provided by financing activities | |||||||||
7,844 | 10,583 | 36,454 | 2,677 | 4,082 | 18,777 | 29,388 | 15,518 | 52,836 | 2,376 |
Decrease in cash and cash equivalents | |||||||||
-6,478 | 1,909 | - | - | - | - | - | - | - | - |
Decrease increase in cash and cash equivalents | |||||||||
- | - | 8,819 | -6,640 | -3,421 | 6,968 | -9,272 | -5,154 | 19,006 | -5,784 |
Supplemental disclosures of cash flow information: | |||||||||
Cash (paid for) received from: | |||||||||
Interest paid | |||||||||
760 | 512 | 56 | 486 | - | - | - | - | - | - |
Income tax benefit | |||||||||
- | 10,419 | - | - | - | - | - | - | - | - |
Cash paid for amounts included in measurement of lease liabilities: | |||||||||
Operating cash flows from lease payments | |||||||||
485 | - | - | - | - | - | - | - | - | - |
Non-cash financing and investing activities | |||||||||
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments | |||||||||
400 | - | - | - | - | - | - | - | - | - |
Fair value of common stock issued as equity issuance costs and charged against paid in capital | |||||||||
- | 450 | - | - | - | - | - | - | - | - |
Fair value of warrants issued in connection with the debt facility | |||||||||
- | 507 | - | - | - | - | - | - | - | - |
Fair value of stock issued in exchange for cancelation of warrants | |||||||||
- | 8 | - | - | - | - | - | - | - | - |
Operating leases | |||||||||
1,797 | - | - | - | - | - | - | - | - | - |
Realized and unrealized (gains) losses, net, on investment securities | |||||||||
12 | 40 | - | - | - | - | - | - | - | - |
Fair value of modification of warrant exercise prices included in paid in capital | |||||||||
- | - | 345 | - | - | - | - | - | - | - |
Fair value of deemed dividend related to modification of warrant exercise prices charged against paid in capital | |||||||||
- | - | -345 | - | - | - | - | - | - | - |
Interest paid | |||||||||
- | - | - | - | 918 | 892 | 637 | 359 | -501 | -31 |
Income taxes | |||||||||
- | - | - | 0 | 0 | - | - | - | - | - |